Credit Suisse Maintains Neutral on Exact Sciences, Raises Price Target to $90
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Dan Leonard maintains a Neutral rating on Exact Sciences (NASDAQ:EXAS) and raises the price target from $75 to $90.
August 04, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Credit Suisse maintains a Neutral rating on Exact Sciences and raises the price target from $75 to $90.
The news is directly about Exact Sciences. The raised price target indicates a positive outlook, but the Neutral rating suggests that the stock is fairly valued at the moment. Therefore, the short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100